Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Not Applicable

• Conditions: Multiple Sclerosis

• Registration Number: NCT00331747
• Lead Sponsor: Sheba Medical Center

Brief Summary

Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients.

During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.

Detailed Description

Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate. The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1 system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped and will also undergo a detailed physical examination by a physical therapist.

Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center.

Repeat gait analysis will be performed after one year of treatment.

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-05-30
• Study First Submitted QC: 2006-05-30
• Study First Posted: 2006-05-31
• Status Verified: 2006-07
• Last Update Submitted: 2006-07-05
• Last Update Posted: 2006-07-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Clinical diagnosis of multiple sclerosis
• EDSS less than 5.5
• No cognitive disability

Exclusion Criteria

• EDSS over 5.5
• Inability to cooperate with gait analysis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Computerized gait analysis: at the beginning of treatment and after 1 year

Trial Locations

Locations (1)

Multiple Sclerosis Center, Sheba Medical Center; 🇮🇱 Tel Hashomer, Israel